Filtered By:
Drug: Xolair
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 1700 results found since Jan 2013.
Anti-IgE for food allergy
CONCLUSIONS: Over the past 20 years, significant progress has been made in understanding the potential role of anti-IgE therapies for food allergy. Anti-IgE therapies appear to be a promising option that may increase reaction dose thresholds and decrease time to reach OIT maintenance and OIT dosing related reactions. Two Phase III trials are currently in progress studying anti-IgE potential monotherapy for the treatment of peanut and multi-food allergies. It is important for clinicians to be aware of these emerging treatment options.PMID:37031775 | DOI:10.1016/j.anai.2023.03.030
Source: Annals of Allergy, Asthma and Immunology - April 9, 2023 Category: Allergy & Immunology Authors: Jennifer A Dantzer Robert A Wood Source Type: research
Allergy —a brave “new world?” Maybe
As allergists and immunologists, we often find ourselves at a crossroads between the elegant and the seemingly simple. From one perspective, we go about our duties manned with a variety of immune-biologics and medications tailormade to manage an array of allergic and inflammatory diseases. Asthma management alone has benefited from the myriad scientific breakthroughs to manage more and more complex diseases. In less than 20 years, we have gone from a single biologic, omalizumab, to more than seven.
Source: Annals of Allergy, Asthma and Immunology - March 31, 2023 Category: Allergy & Immunology Authors: James M. Tracy Tags: Editorial Source Type: research
Analysis of the Efficacy and Recurrence of Omalizumab Use in the Treatment of Chronic Spontaneous Urticaria and Chronic Inducible Urticaria
Conclusion: Omalizumab was effective and safe for CSU and CIndU patients. Patients with CSU responded more quickly to omalizumab and showed a relatively better treatment effect. However, there was a possibility of relapse after discontinuation of omalizumab after complete control of CU, and in these cases, restarting omalizumab treatment after relapse was effective.Int Arch Allergy Immunol
Source: International Archives of Allergy and Immunology - March 30, 2023 Category: Allergy & Immunology Source Type: research
Comparison of the clinical outcomes of patients with NSAID-exacerbated respiratory disease receiving aspirin or biologicals
CONCLUSIONS: In NERD patients, mepolizumab significantly decreased blood eosinophil counts and recurrent FESS. There was no significant difference between the patients receiving ATAD or mepolizumab regarding other clinical parameters.PMID:36971076 | DOI:10.1080/02770903.2023.2196567
Source: Journal of Asthma - March 27, 2023 Category: Respiratory Medicine Authors: G ülseren Tuncay Ebru Damadoglu Melek Cihanbeylerden Ozge Can Bostan Hazal Kay ıkcı Serdar Özer G ül Karakaya Ali Fuat Kalyoncu Source Type: research
Omalizumab ameliorates extrarespiratory symptoms in patients with aspirin-exacerbated respiratory disease
Omalizumab, an anti-IgE antibody, has clinical efficacy against respiratory symptoms of aspirin-exacerbated respiratory disease (AERD). However, some patients with AERD also present with extrarespiratory (chest, gastrointestinal, and/or cutaneous) symptoms, which are resistant to conventional treatment but can be alleviated by systemic corticosteroids.
Source: Journal of Allergy and Clinical Immunology - March 24, 2023 Category: Allergy & Immunology Authors: Hiroaki Hayashi, Yuma Fukutomi, Chihiro Mitsui, Keiichi Kajiwara, Kentaro Watai, Yasuhiro Tomita, Yosuke Kamide, Takahiro Tsuburai, Kiyoshi Sekiya, Makoto Ishii, Yoshinori Hasegawa, Masami Taniguchi Tags: Brief report Source Type: research
Omalizumab ameliorates extra-respiratory symptoms in patients with aspirin-exacerbated respiratory disease
Omalizumab, an anti-immunoglobulin E antibody, has clinical efficacy against respiratory symptoms of aspirin-exacerbated respiratory disease (AERD). However, some patients with AERD also present with extra-respiratory (chest, gastrointestinal, and/or cutaneous) symptoms, which are resistant to conventional treatment but can be alleviated by systemic corticosteroids.
Source: Journal of Allergy and Clinical Immunology - March 24, 2023 Category: Allergy & Immunology Authors: Hiroaki Hayashi, Yuma Fukutomi, Chihiro Mitsui, Keiichi Kajiwara, Kentaro Watai, Yasuhiro Tomita, Yosuke Kamide, Takahiro Tsuburai, Kiyoshi Sekiya, Makoto Ishii, Yoshinori Hasegawa, Masami Taniguchi Source Type: research
B Lineage Cells and IgE in Allergic Rhinitis and CRSwNP and the Role of Omalizumab Treatment
CONCLUSION: This review highlights current knowledge of the roles of B cells and IgE in the pathogenesis of AR and CRSwNP and a small comparison between the 2 diseases. More systemic studies should be done to elevate the understanding of these diseases and their treatment.PMID:36848269 | DOI:10.1177/19458924221147770
Source: American Journal of Rhinology and Allergy - February 27, 2023 Category: ENT & OMF Authors: Junqin Bai Bruce K Tan Source Type: research
